Rasburicase in Tumor Lysis Syndrome
- Registration Number
- NCT00302653
- Lead Sponsor
- Sanofi
- Brief Summary
The purpose of this study is to determine whether rasburicase is effective and safety in correcting hyperuricemia.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 33
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description 1 Rasburicase Rasburicase 0,20mg/Kg/Day once a day 3-7 days
- Primary Outcome Measures
Name Time Method Percentage of patients with uric acid greater-than-normal laboratory levels (hyperuricemia) 28 (+- 3) days after the last dose of rasburicase Adverse events occurrence During the study
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms of rasburicase contribute to uric acid reduction in tumor lysis syndrome?
How does rasburicase compare to allopurinol in managing hyperuricemia in pediatric oncology patients?
Are there specific biomarkers that predict rasburicase efficacy in tumor lysis syndrome patients?
What are the most common adverse events associated with rasburicase in children and adolescents?
What combination therapies with rasburicase are being explored for tumor lysis syndrome treatment?
Trial Locations
- Locations (1)
Sanofi-aventis administrative office
🇧🇷São Paulo, Brazil
Sanofi-aventis administrative office🇧🇷São Paulo, Brazil